Related Experiment Video
Updated: May 21, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Neoadjuvant and adjuvant treatment of renal cell carcinoma
Kiruthikah Thillai1, Suzanne Allan, Thomas Powles
1Department of Medical Oncology, Guy's Hospital, London, UK.
Abstract:
Locally advanced renal cell cancers have a significant recurrence rate following radical nephrectomy. Traditional cytotoxic chemotherapy and immunotherapy have failed to demonstrate a benefit in the adjuvant setting. Recent advances in the treatment of metastatic renal cell carcinoma using agents that target VEGF and the mTOR pathways have radically changed the way metastatic renal cell carcinoma is treated. These drugs may be able to reduce the rate of recurrence in high-risk disease, and are now being assessed in the neoadjuvant and adjuvant settings. This review summarizes the evidence for targeted treatment in both the neoadjuvant and adjuvant setting, and its use with cytoreductive nephrectomy.
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Tumor Immunotherapy
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Kidney Transplant III: Nursing Management
Chronic Kidney Disease III: Interprofessional Care
Treatment Resistant Cancers

